Yves Dutronc

2.7k total citations · 1 hit paper
60 papers, 1.9k citations indexed

About

Yves Dutronc is a scholar working on Urology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Yves Dutronc has authored 60 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Urology, 23 papers in Dermatology and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Yves Dutronc's work include Hair Growth and Disorders (33 papers), Autoimmune Bullous Skin Diseases (16 papers) and Dermatology and Skin Diseases (13 papers). Yves Dutronc is often cited by papers focused on Hair Growth and Disorders (33 papers), Autoimmune Bullous Skin Diseases (16 papers) and Dermatology and Skin Diseases (13 papers). Yves Dutronc collaborates with scholars based in United States, Japan and France. Yves Dutronc's co-authors include Steven A. Porcelli, Brett King, C. Paul, Justin Ko, Natasha Atanaskova Mesinkovska, Carsten Henneges, Petr A. Illarionov, Alberto Molano, Gurdyal S. Besra and Jin S. Im and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Yves Dutronc

57 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

2023 65 citations Ohsang Kwon, Maryanne M. Senna et al. American Journal of Clinical Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yves Dutronc United States	24	1.1k	816	442	438	269	60	1.9k
Madeleine Duvic United States	18	558 0.5×	711 0.9×	125 0.3×	463 1.1×	101 0.4×	30	1.5k
Kunal Malik United States	18	277 0.3×	964 1.2×	87 0.2×	110 0.3×	215 0.8×	39	1.4k
Ravi Hiremagalore India	8	611 0.6×	331 0.4×	38 0.1×	132 0.3×	115 0.4×	22	878
Takeya Adachi Japan	13	446 0.4×	254 0.3×	99 0.2×	45 0.1×	46 0.2×	45	1000
Alice B. Gottlieb United States	10	533 0.5×	339 0.4×	39 0.1×	94 0.2×	84 0.3×	19	915
Assi Levi Israel	15	178 0.2×	373 0.5×	26 0.1×	130 0.3×	150 0.6×	73	882
Helmut Beltraminelli Switzerland	18	81 0.1×	466 0.6×	21 0.0×	442 1.0×	236 0.9×	60	1.1k
Anna Haemel United States	14	347 0.3×	143 0.2×	14 0.0×	217 0.5×	122 0.5×	40	1.0k
U. Zimmermann France	20	55 0.1×	587 0.7×	76 0.2×	173 0.4×	36 0.1×	51	1.3k
Razieh Soltani‐Arabshahi Iran	13	303 0.3×	261 0.3×	20 0.0×	41 0.1×	203 0.8×	19	679

Countries citing papers authored by Yves Dutronc

Since Specialization

Citations

This map shows the geographic impact of Yves Dutronc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Dutronc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Dutronc more than expected).

Fields of papers citing papers by Yves Dutronc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves Dutronc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Dutronc. The network helps show where Yves Dutronc may publish in the future.

Co-authorship network of co-authors of Yves Dutronc

This figure shows the co-authorship network connecting the top 25 collaborators of Yves Dutronc. A scholar is included among the top collaborators of Yves Dutronc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves Dutronc. Yves Dutronc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ko, Justin, Ohsang Kwon, Sergio Vañó‐Galván, et al.. (2024). Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata. JAMA Dermatology. 160(10). 1075–1075. 14 indexed citations

Senna, Maryanne M., Arash Mostaghimi, Manabu Ohyama, et al.. (2024). Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal of the European Academy of Dermatology and Venereology. 38(3). 583–593. 21 indexed citations

King, Brett, Manabu Ohyama, Maryanne M. Senna, et al.. (2024). Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2. Journal of the American Academy of Dermatology. 92(2). 299–306. 4 indexed citations

Taylor, Susan C., Neil J. Korman, Tsen‐Fang Tsai, et al.. (2023). Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2. Dermatology and Therapy. 13(12). 3181–3191. 7 indexed citations

Ko, Justin, Wilma F. Bergfeld, Yves Dutronc, et al.. (2023). Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology. 159(9). 970–970. 9 indexed citations

Craiglow, Brittany G., Yang Won Lee, Sergio Vañó‐Galván, et al.. (2023). 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials. Journal of the American Academy of Dermatology. 89(3). AB55–AB55. 1 indexed citations

Kwon, Ohsang, Maryanne M. Senna, Rodney Sinclair, et al.. (2023). Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). American Journal of Clinical Dermatology. 24(3). 443–451. 65 indexed citations breakdown →

Senna, Maryanne M., Ohsang Kwon, Bianca Maria Piraccini, et al.. (2023). Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatology and Therapy. 13(12). 3209–3220. 2 indexed citations

King, Brett, Jerry Shapiro, Manabu Ohyama, et al.. (2023). Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib. SKIN The Journal of Cutaneous Medicine. 7(2). s184–s184. 1 indexed citations

10.

King, Brett, Manabu Ohyama, Maryanne M. Senna, et al.. (2023). 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2. Journal of the American Academy of Dermatology. 89(3). AB69–AB69. 1 indexed citations

11.

King, Brett, Jerry Shapiro, Manabu Ohyama, et al.. (2023). When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. British Journal of Dermatology. 189(6). 666–673. 25 indexed citations

12.

King, Brett, Arash Mostaghimi, Yutaka Shimomura, et al.. (2022). Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal of Dermatology. 188(2). 218–227. 37 indexed citations

13.

Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2020). The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. British Journal of Dermatology. 183(4). 702–709. 67 indexed citations

14.

Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2020). Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. British Journal of Dermatology. 183(6). 1065–1072. 27 indexed citations

15.

Aldhouse, Natalie V. J., Helen Kitchen, S.L. Knight, et al.. (2020). “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata. Journal of Patient-Reported Outcomes. 4(1). 76–76. 57 indexed citations

16.

Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2020). Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. American Journal of Clinical Dermatology. 21(5). 725–732. 41 indexed citations

17.

Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2020). The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms. Journal of Investigative Dermatology Symposium Proceedings. 20(1). S71–S77. 5 indexed citations

18.

Yu, Karl O. A., Jin S. Im, Alberto Molano, et al.. (2005). Modulation of CD1d-restricted NKT cell responses by using N- acyl variants of α-galactosylceramides. Proceedings of the National Academy of Sciences. 102(9). 3383–3388. 288 indexed citations

19.

Forestier, Claire, Alberto Molano, Jin S. Im, et al.. (2005). Expansion and Hyperactivity of CD1d-Restricted NKT Cells during the Progression of Systemic Lupus Erythematosus in (New Zealand Black × New Zealand White)F1 Mice. The Journal of Immunology. 175(2). 763–770. 48 indexed citations

20.

Bonish, Brian K., D. Jullien, Yves Dutronc, et al.. (2000). Overexpression of CD1d by Keratinocytes in Psoriasis and CD1d-Dependent IFN-γ Production by NK-T Cells. The Journal of Immunology. 165(7). 4076–4085. 181 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact